← 返回

用于口腔黏膜炎管理的局部间充质干细胞来源条件培养基凝胶的临床前疗效与安全性评价

英文原题:Preclinical efficacy and safety evaluation of a topical mesenchymal stem cell derived conditioned media gel for oral mucositis management.

查看英文原题

Preclinical efficacy and safety evaluation of a topical mesenchymal stem cell derived conditioned media gel for oral mucositis management.

PubMed 2026/02/24(内容时间) Sci Rep Q1 · IF 4.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

化疗/放疗诱发的口腔黏膜炎(OM)带来显著临床挑战,常导致疼痛、营养不良、治疗延迟及生活质量下降。再生医学已显示出伤口护理方面的益处。

因此,本研究旨在临床前模型中评估间充质干(基质)细胞条件培养液(MSC-CM)制剂(5%、10%和15%)对5-氟尿嘧啶(5-FU)诱导的OM及放射性伤口的安全性和治疗效果。大鼠/小鼠28天口服毒性研究显示,各治疗组制剂均未产生与治疗相关的不良反应。MSC-CM浓度为100%时确定为未观察到不良反应剂量(NOAEL)。在5-FU诱导的OM模型中,MSC-CM制剂呈剂量依赖性获益,包括显著降低溃疡大小/严重程度、促进黏膜上皮再生,并改善受5-FU损害的血液学、生化、肝脏、肾脏和免疫学指标。组织病理学评估显示,MSC-CM治疗显著减少化疗诱导的黏膜增生和水疱形成。这些结果提示组织修复能力增强,可能由自噬相关机制介导。15%制剂疗效最佳,生存率为100%、平均溃疡愈合评分为71.9%,并实现近乎完全的黏膜恢复;其次为10%和5%制剂。在放射性伤口愈合模型中,给予10%和15% MSC-CM制剂耐受性良好,体重保持稳定;与对照组相比,红斑、脱毛、伤口潮湿及渗液均明显减少。

值得注意的是,10%制剂促进伤口更快闭合,最早于第4–7天即可见显著愈合。从机制上看,这可能归因于伤口愈合凝胶(WHG)在损伤部位治疗后诱导小鼠分泌IL-20和IL-17A/F,进而促进放射性伤口修复和再生。

总之,这些发现表明MSC-CM局部制剂是安全有效的候选疗法,可减轻化疗和放疗毒性并促进组织再生,支持其转化应用潜力。

展开英文摘要原文

Chemotherapy / radiation induced oral mucositis (OM) poses significant clinical challenges, often leading to pain, malnutrition, treatment delays, and reduced quality of life. Regenerative medicine has been shown to have beneficial value in wound care. Hence, the current study was aimed at evaluating the safety and therapeutic efficacy of Mesenchymal Stem (Stromal) Cell derived Conditioned Media (MSC-CM) formulations (5%, 10%, and 15%) in preclinical models of 5-fluorouracil (5-FU) induced OM and radiation wounds. The 28-day oral toxicity studies in rats/mice established that the formulations across treatment groups produced no treatment-related adverse effects.

The NOAEL was established at 100% MSC-CM concentration. In the 5-FU based OM model, treatment with MSC-CM formulations demonstrated dose-dependent benefits, including significant reductions in ulcer size/ severity, regeneration of mucosal epithelium, and improvements in hematological, biochemical, hepatic, renal, and immunological parameters compromised by 5-FU. Histopathological evaluation revealed that chemotherapy-induced mucosal hyperplasia and blister formation were markedly reduced following MSC-CM treatment.

These findings suggested enhanced tissue repair, possibly mediated through autophagy-associated mechanisms. The 15% formulation was most efficacious, yielding 100% survival, a mean ulcer healing score of 71. 9%, and near-complete mucosal recovery, followed by 10% and 5% formulations. In the radiation wound healing model, administration of 10% and 15% MSC-CM formulations was well tolerated, as evidenced by stable body weights, and produced visible reductions in redness, hair loss, wound wetness, and oozing compared to controls.

Notably, the 10% formulation promoted accelerated wound closure, with significant wound healing as early as day 4 7.

Mechanistically, this could be attributed to induction of secretory IL-20 and IL-17 A/F in mice after wound healing gel (WHG) treatment at site of injury, which led to repair and regeneration of radiation-induced wounds. Collectively, these findings establish MSC-CM based topical formulations as safe and effective therapeutic candidates for mitigating chemotherapy and radiation induced toxicities, enhancing tissue regeneration, thereby supporting its translational potential in oral mucositis.

论文信息

作者
Mathen C、Dsouza W、Sharma D、Pradhan TN、Kesarwani A、Gujar D、Choudhary ML、Nithyanand A
第一作者单位
Clinical R&D, OCT Therapies and Research Pvt Ltd Mumbai, Maharashtra, 400078, India. caroline@octtherapies.com.India
通讯作者单位
Kode Lab, Tumor Immunology & Immunotherapy Group, Advanced Center for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, 410210, India. jkode@actrec.gov.in.India
期刊
Scientific reports2026 Feb 24
原文标识
PubMed 41735417 · DOI 10.1038/s41598-026-40193-3